Cardiol Therapeutics (CRDL) Current Assets (2020 - 2026)

Cardiol Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $22.8 million for Q1 2026.

• Quarterly Current Assets rose 29.45% year-over-year to $22.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.8 million (up 29.45% YoY) and the FY2025 annual result came in at $16.9 million, down 25.66% from the prior year.
• Current Assets was $22.8 million for Q1 2026 at Cardiol Therapeutics, up from $16.9 million in the prior quarter.
• Across five years, Current Assets topped out at $62.2 million in Q1 2022 and bottomed at $9.3 million in Q3 2025.
• A 5-year average of $29.8 million and a median of $22.8 million in 2026 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets surged 111.37% — and 2024, when it slumped 59.99%.
• Cardiol Therapeutics' Current Assets stood at $45.3 million in 2022, then tumbled by 41.33% to $26.6 million in 2023, then retreated by 14.63% to $22.7 million in 2024, then slipped by 25.66% to $16.9 million in 2025, then jumped by 35.29% to $22.8 million in 2026.
• Business Quant data shows CRDL's Current Assets at $22.8 million in Q1 2026, $16.9 million in Q4 2025, and $9.3 million in Q3 2025.